Table of Contents
Introduction
The Evaluation of Biological Agents, Vibeke Strand and David L. Scott
Cellular Targeted Therapies
Anti-CD5 Ricin A Chain Immunoconjugate Therapy in Rheumatoid Arthritis, John J. Cash
Early Clinical Studies of IL-2 Fusion Toxin in Patients with Severe Rheumatoid Arthritis
Recent-Onset Insulin-Dependent Diabetes Mellitus, and Psoriasis, Thasia G. Woodworth and Karen Parker
Chimeric Anti-CD4 Antibody as a Potential Therapeutic Agent for Rheumatoid Arthritis, Larry W. Moreland and William J. Koopman
CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis, F. C. Breedveld
The Use of CE9.1, a Primatized Monoclonal Anti-CD4, in the Treatment of Rheumatoid Arthritis, David E. Yocum, Alan M. Solinger, and John Lipani
CAMPATH-1H Therapy in Autoimmune Diseases, Richard A. Watts and John D. Isaacs
CAMPATH-1H in Rheumatoid Arthritis: United States Experience, David E. Yocum and Jeffrey M. Johnston
Cytokine Targeted Therapies
Interferon-Gamma in the Treatment of Rheumatoid Arthritis, Eric M. Veys, Herman Mielants, and Gust Verbruggen
Tumor Necrosis Factor Blockade in Rheumatoid Arthritis, Michael J. Elliott, Marc Feldmann, and Ravinder N. Maini
Engineered Human Anti-Tumor Necrosis Factor-Alpha (TNFaAntibody, CDP571, in Rheumatoid Arthritis, Ernest H. S. Choy and Gabriel S. Panayi
Clinical Experience with Recombinant Human Interleukin-1 Receptor Type I (Rhu IL-1RI) in Patients with Rheumatoid Arthritis, Richard M. Pope, Barbara Drevlow, Jennifer Capezio, Rosa Lovis, and Alan Landay
Treatment of Rheumatoid Arthritis with Soluble Tumor Necrosis Factor Receptor, Gary R. Margolies, William J. Koopman, and Larry W. Moreland
Adhesion Molecule Targeted Therapies
Treatment of Rheumatoid Arthritis with a Monoclonal Antibody to Intercellular Adhesion Molecule-1, Arthur F. Kavanaugh and Peter E. Lipsky
Potential Antigen-Specific Therapies
T-Cell-Receptor Peptide Therapy for Multiple Sclerosis, Arthur A. Vanderbark, Dennis N. Bourdette, Ruth H. Whitham, and Halina Offner
T-Cell Receptor Peptide Vaccination Studies in Rheumatoid Arthritis, Louis W. Heck, Larry W. Moreland, and William J. Koopman
Oral Tolerance for the Treatment of Autoimmune Disease, David A Hafler and Howard L. Weiner
Oral Tolerance, David E. Trentham
Intravenous Immunoglobulin (IVIg) in the Treatment of Autoimmune Diseases, Vibeke Strand and Martin L. Lee
Purine and Pyrimidine Synthesis Inhibitors
Inhibitors of De Novo Nucleotide Synthesis in the Treatment of Rheumatoid Arthritis, Robert I. Fox and Randall E. Morris
Leflunomide: A New Immunosuppressive Drug, David L. Scott and Vibeke Strand
Future Directions
An Assessment of Novel Agents in the Treatment of the Rheumatic Diseases, Vibeke Strand and Lee S. Simon
